BUZZ-摩根大通给予 Vor Bio "增持 "评级，Vor Bio 大幅上涨

路透中文

Dec 09, 2025

BUZZ-<a href="https://laohu8.com/S/JPM">摩根大通</a>给予 Vor Bio "增持 "评级，Vor Bio 大幅上涨

12月9日 - ** Vor生物制药公司VOR.O股价盘前上涨67%至13.97美元

** 摩根大通（J.P.Morgan）开始给予 "增持 "评级，目标价为43美元，与该股上次收盘价相比上涨了414%。

** 券商称，由于来自中国的强劲的后期数据，VOR从中国的RemeGen688331.SS公司获得许可的自身免疫性疾病药物泰利昔普（telitacicept）被认为是 "在一系列适应症中风险极低的药物"。

** Telitacicept 正被开发用于治疗肌无力症（一种肌肉衰弱疾病）和原发性斯约金氏病（一种导致眼睛和口腔干燥的疾病）。

** 摩根大通（J.P.Morgan）"保守地假定() telitacicept 仅在美国这两个适应症的销售峰值"。

** 鉴于 "仅在 MG 和 pSD 领域，替立替塞普经概率调整后的价值"，目前的股价被认为被低估了 - 摩根大通

** 今年以来股价下跌了 62

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590343352"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590343352\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590343352?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-12-09 19:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590343352","market":"hk","top_or_hot":-1,"title":"BUZZ-摩根大通给予 Vor Bio \"增持 \"评级，Vor Bio 大幅上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/JPM\">摩根大通</a>给予 Vor Bio \"增持 \"评级，Vor Bio 大幅上涨</title></head><body><p><span>12月9日</span><span> - </span>** Vor生物制药公司<span>VOR.O</span>股价盘前上涨67%至13.97美元</p><p>** 摩根大通（J.P.Morgan）<span>开始 </span>给予 \"增持 \"评级，目标价为43美元，与该股上次收盘价相比上涨了414%。</p><p>** 券商称，由于来自中国的强劲的后期数据，VOR从中国的RemeGen<span>688331.SS</span>公司获得许可的自身免疫性疾病药物泰利昔普（telitacicept）被认为是 \"在一系列适应症中风险极低的药物\"。</p><p>** Telitacicept 正被开发用于治疗肌无力症（一种肌肉衰弱疾病）和原发性斯约金氏病（一种导致眼睛和口腔干燥的疾病）。</p><p>** 摩根大通（J.P.Morgan）\"保守地假定() telitacicept 仅在美国这两个适应症的销售峰值\"。</p><p>** 鉴于 \"仅在 MG 和 pSD 领域，替立替塞普经概率调整后的价值\"，目前的股价被认为被低估了 - 摩根大通 </p><p>** 今年以来股价下跌了 62</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-摩根大通给予 Vor Bio \"增持 \"评级，Vor Bio 大幅上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-摩根大通给予 Vor Bio \"增持 \"评级，Vor Bio 大幅上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-12-09 19:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/JPM\">摩根大通</a>给予 Vor Bio \"增持 \"评级，Vor Bio 大幅上涨</title></head><body><p><span>12月9日</span><span> - </span>** Vor生物制药公司<span>VOR.O</span>股价盘前上涨67%至13.97美元</p><p>** 摩根大通（J.P.Morgan）<span>开始 </span>给予 \"增持 \"评级，目标价为43美元，与该股上次收盘价相比上涨了414%。</p><p>** 券商称，由于来自中国的强劲的后期数据，VOR从中国的RemeGen<span>688331.SS</span>公司获得许可的自身免疫性疾病药物泰利昔普（telitacicept）被认为是 \"在一系列适应症中风险极低的药物\"。</p><p>** Telitacicept 正被开发用于治疗肌无力症（一种肌肉衰弱疾病）和原发性斯约金氏病（一种导致眼睛和口腔干燥的疾病）。</p><p>** 摩根大通（J.P.Morgan）\"保守地假定() telitacicept 仅在美国这两个适应症的销售峰值\"。</p><p>** 鉴于 \"仅在 MG 和 pSD 领域，替立替塞普经概率调整后的价值\"，目前的股价被认为被低估了 - 摩根大通 </p><p>** 今年以来股价下跌了 62</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2148510915.USD","symbol_name":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL4T3XF0W8:1","article_id":"2590343352","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590343352","pubTimestamp":1765280968,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-摩根大通给予 Vor Bio \"增持 \"评级，Vor Bio 大幅上涨12月9日 - ** Vor生物制药公司VOR.O股价盘前上涨67%至13.97美元** 摩根大通开始 给予 \"增持 \"评级，目标价为43美元，与该股上次收盘价相比上涨了414%。** 摩根大通\"保守地假定() telitacicept 仅在美国这两个适应症的销售峰值\"。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688331":"荣昌生物","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0239":"医药制造","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","VOR":"Vor Biopharma Inc.","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK4139":"生物科技"},"translate_title":"BUZZ-Vor Bio jumps as JPMorgan gives \"overweight\" rating","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":0.9,"VOR":0.9},"content_text":"BUZZ-摩根大通给予 Vor Bio \"增持 \"评级，Vor Bio 大幅上涨12月9日 - ** Vor生物制药公司VOR.O股价盘前上涨67%至13.97美元** 摩根大通（J.P.Morgan）开始 给予 \"增持 \"评级，目标价为43美元，与该股上次收盘价相比上涨了414%。** 券商称，由于来自中国的强劲的后期数据，VOR从中国的RemeGen688331.SS公司获得许可的自身免疫性疾病药物泰利昔普（telitacicept）被认为是 \"在一系列适应症中风险极低的药物\"。** Telitacicept 正被开发用于治疗肌无力症（一种肌肉衰弱疾病）和原发性斯约金氏病（一种导致眼睛和口腔干燥的疾病）。** 摩根大通（J.P.Morgan）\"保守地假定() telitacicept 仅在美国这两个适应症的销售峰值\"。** 鉴于 \"仅在 MG 和 pSD 领域，替立替塞普经概率调整后的价值\"，目前的股价被认为被低估了 - 摩根大通 ** 今年以来股价下跌了 62(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}